Core Insights - Eli Lilly has achieved significant success in the GLP-1 drug market, with a stock price increase of 200% over the past three years and a leadership position in the U.S. market, holding over 60% market share [1][6][10] - The obesity drug market is projected to reach nearly $100 billion by the end of the decade, indicating potential for continued growth for Eli Lilly [7] Company Performance - Eli Lilly's revenue has shown double-digit growth, with Mounjaro and Zepbound generating over $11 billion in revenue during the recent quarter, both experiencing triple-digit revenue gains [1][6] - The company's gross margin stands at 85.40%, and it has a market capitalization of $988 billion [9] Product Overview - GLP-1 drugs, including Eli Lilly's tirzepatide (Mounjaro and Zepbound), help manage blood sugar levels and appetite, contributing to their popularity [4][5] - Eli Lilly is also developing orforglipron, an oral weight loss candidate currently under regulatory review, which could further enhance its market position [5][9] Competitive Landscape - While Novo Nordisk was the first to market with GLP-1 drugs, Eli Lilly has been gaining market share and has outperformed competitors in clinical trials [6][9] - Other companies, such as Pfizer and Viking Therapeutics, are looking to enter the market, but Eli Lilly's established brand strength and product efficacy are expected to sustain its revenue growth [10]

I think it’s fair to say that it’s been a really tough time lately for Novo Nordisk A/S ( NVO ) shareholders. It looked as if the oral Wegovy approval just daysI’ve managed my investments since 1999, gaining perspective across multiple market cycles. With a background in Economics and ongoing CFA certification, my focus is on uncovering mispriced assets that the market has overlooked. I conduct my analyses in a way that allows me to use them myself — not just casually handed-out buy or sell decisions. While ...

Core Insights - Novo Resources Corp. has provided an update on the Wyloo Project, highlighting recent exploration results and a forward work program, including a maiden RC drilling program planned for Q2 2026 to test the Wyloo SE polymetallic vein system [2][3][19]. Exploration Results - Recent soil sampling at Wyloo SE has defined a strong, open-ended multielement anomaly over a known polymetallic vein system, with peak soil values of 57.2 ppm Ag, 142 ppm Sb, 1,440 ppm As, 2,180 ppm Zn, and 1,530 ppm Pb [5][11]. - Follow-up stream sediment sampling at Wyloo SW has expanded the original anomaly, defining a target area of 2.5 km x 800 m with peak stream sediment results of 19.9 ppm Sb and a multielement association of Sb-As-Cu-Pb-Zn [4][15]. Geological Context - The Wyloo project area is located in the southern Pilbara, with the Wyloo SE and SW prospects situated within the core of the Wyloo anticline, forming a basement high within the Ashburton Basin [6][28]. - The geological setting includes a dynamic tectonic environment with the Nanjilgardy Fault located just 5 km south of the prospect [6]. Planned Activities - A heritage survey is scheduled for March 2026 to facilitate access for the planned RC drilling at Wyloo SE [5][19]. - The maiden drilling program will target the ENE trending vein array, the Tasha Fault Zone, and soil anomalies parallel to stratigraphy, aiming to assess the vertical metal zonation and potential plunge of the target [19][20]. Historical Context - Significant antimony anomalies were identified in 2023 during routine stream sediment sampling, leading to further exploration that revealed a zone of quartz-sulphide veining with anomalous antimony, silver, gold, and base metals at Wyloo SE [7][9]. - Previous rock chip sampling yielded peak assay results of 387 g/t Ag, 0.38% Sb, 5.0% Pb, 1.6% Zn, 2.4% Cu, and 0.52 g/t Au, enhancing the target's potential [7].

And we're about 2 minutes away from the end of the trading day. Katie Greifeld and Matt Miller here, Romaine Bostick on assignment here to help take us through the closing balance. That global sign has joined now by Carol Massar and Tim Stenovec.We bring together all of our different audiences across television, radio and YouTube and show you. Take a look at the market reaction today. It's not quite the rally that we saw on Friday, but pretty dang good.Yeah, and listen, what we're talking about maybe anothe ...

More broadly. I mean, what we do at IDO is understand how ads impact people's behaviour. We call it outcome measurement.So like Nielsen measures audiences, we measure the behavioural changes from every ad across all of linear and streaming. How do you do that. We're looking at massive panels of people who are privacy in a privacy safe way, are being tracked through their day.We're also a huge consumer of Google's anonymous data that comes out through what they call Google Trends. And we're aggregating all t ...

Group 1 - Major stock indexes, including Dow Jones and S&P 500, experienced a decline of 0.2% as Wall Street awaited the rescheduled January jobs report [1] - Monday.com, an artificial intelligence stock, reported a disappointing full-year outlook, leading to a significant drop in its shares despite beating Q4 estimates [1][1] - The overall sentiment in the market is cautious as investors are closely monitoring upcoming economic data [1] Group 2 - Hims & Hers halted its Wegovy knockoff after just two days, indicating potential regulatory challenges from the FDA [1] - Novo Nordisk's stock faced a two-day plunge as the CFO acknowledged "extraordinary challenges" for 2026, reflecting concerns about the company's future performance [1] - Eli Lilly is highlighted as a strong stock performer amid increasing competition with Novo Nordisk, suggesting a shift in market dynamics within the biotech sector [1]

>> THIS IS "BLOOMBERG BUSINESS WEEK DAILY." REPORTING FROM THE MAGAZINE THAT HELPS GLOBAL LEADERS STAY AHEAD, WITH INSIGHT ON THE PEOPLE, COMPANIES, AND TRENDS SHAPING TODAY’S COMPLEX ECONOMY. PLUS GLOBAL BUSINESS, FINANCE, AND TECH NEWS AS IT HAPPENS. "BLOOMBERG BUSINESS WEEK DAILY" WITH CAROL MASSAR AND TIM STENOVEC.LIVE ON BLOOMBERG RADIO, TELEVISION, YOUTUBE, AND BLOOMBERG ORIGINALS. CAROL: VERY GOOD AFTERNOON, EVERYBODY, ACROSS BLOOMBERG PLATFORMS, WELCOME TO "BLOOMBERG BUSINESS WEEK DAILY." I’M CAROL ...

Pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) revealed today it is pursuing legal action against Hims & Hers Health Inc (NYSE:HIMS) for alleged patent infringement, after the telehealth giant introduced a weight-loss pill with the same active ingredient as its Wegovy drug -- priced at $149 -- at a much lower starting price of $49. Hims & Hers Health stopped offering the medication on Saturday, following threats of legal action from the U.S. Food and Drug Administration (FDA) and Novo Nordisk. The FDA als ...

The Danish drugmaker’s patent lawsuit is the company’s latest effort to shore up its place in the booming weight-loss drug market. https://t.co/SHlDTxFFTk ...

Bring in show music, please. >> This is SquawkPod and I'm CNBC producer Cameron Costa. On today's episode, The Morning After, breaking down a Super Bowl with super costly ads.I think this was the first Super Bowl where people were really talking about AI >> and painting America's economic future with director of the president's National Economic Council and one-time Federal Reserve chair contender Kevin Hasset. >> I absolutely believe that we're on an uptick that's significant. I think that the open questio ...